CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity

Core Insights - CytoDyn Inc. has been selected for a poster and oral presentation at the AACR Special Conference in Cancer Research, focusing on the effects of leronlimab on metastatic triple-negative breast cancer [1][2] Presentation Details - The oral presentation will be delivered by Dr. Richard Pestell, highlighting the impact of leronlimab on metastatic triple-negative breast cancer [2] - The poster presentation is scheduled for September 26, 2025, from 6:30 p.m. to 8:30 p.m. EDT, while the podium presentation will take place on September 27, 2025, from 10:25 a.m. to 10:40 a.m. EDT [4] Research Findings - Preliminary findings suggest that leronlimab may convert 'cold' tumors into 'hot' tumors, enhancing their responsiveness to checkpoint inhibitors, particularly in aggressive metastatic triple-negative breast cancer [3] - The research aims to elucidate the mechanism of action for leronlimab, which may have broad applicability for solid tumors with limited treatment options [3] Company Overview - CytoDyn is a clinical-stage biotechnology company focused on advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, which plays a crucial role in immune function related to cancer and other diseases [5]